Hematology

Latest News

Lori A. Leslie, MD | Image: John A. Theurer Cancer Center
Phase 2 Study Shows Feasibility of Axi-Cel Delivery in Outpatient Setting

September 13th 2025

Outpatient treatment with axi-cel shows promising response rates for relapsed large B-cell lymphoma, enhancing accessibility in community oncology settings.

The iRR6 may help identify those who are unlikely to derive long-term benefit from ruxolitinib and could be considered for alternative therapies. | Image credit: mdaros - stock.adobe.com
Refined iRR6 Model Improves Risk Stratification in Intermediate-1 Myelofibrosis

September 12th 2025

The study adds important data about how people with hematologic malignancies are affected by COVID-19 infection. | Image credit: Tyler Olson -stock.adobe.com
COVID-19 Risk Remains High for Patients With Hematologic Malignancies

September 10th 2025

While immunogenicity is often reduced, vaccination remains indispensable in multiple myeloma, according to the review. | Image credit: alernon77 - stock.adobe.com
Vaccination Remains Essential in Multiple Myeloma Despite Impaired Responses

September 4th 2025

Patients with an inflammatory transcriptome profile at 3 months had a greater risk of an infection. | Image credit: Saiful52 - stock.adobe.com
Immune Profiling May Help Gauge Infection Risk in Patients With CLL

August 31st 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Considerations for Designing ePRO Interventions for Patients With RRMM
December 4th 2020

Considerations for Designing ePRO Interventions for Patients With RRMM

Skylar Jeremias
Patients and health care providers evaluated the use of an electronic patient-reported outcome (ePRO) intervention for use in a clinic setting for patients with relapsed or refractory multiple myeloma (RRMM).
Review Examines New Options for Patients With Aplastic Anemia
November 28th 2020

Review Examines New Options for Patients With Aplastic Anemia

AJMC Staff
Severe aplastic anemia used to have few options and mortality was high, but a new class of drugs offers some hope.
Real-World Data Confirm KRd Safety, Efficacy in RRMM
November 26th 2020

Real-World Data Confirm KRd Safety, Efficacy in RRMM

Jared Kaltwasser
New real-world data confirms that carfilzomib, lenalidomide, and dexamethasone (KRd) are a safe and effective option for patients with relapsed or refractory multiple myeloma.
Selinexor Shows Promise in Combination With Daratumumab, Dexamethasone in RRMM
November 20th 2020

Selinexor Shows Promise in Combination With Daratumumab, Dexamethasone in RRMM

Jared Kaltwasser
The oral selective inhibitor of nuclear export could provide a new therapeutic avenue in daratumumab-naive patients with relapsing refractory multiple myeloma (RRMM).
Hypercalcemia in Multiple Myeloma Leads to Poor Prognosis
November 18th 2020

Hypercalcemia in Multiple Myeloma Leads to Poor Prognosis

Jared Kaltwasser
New research attempts to answer some of the mystery related to the causes and impact of hypercalcemia in patients with newly diagnosed multiple myeloma.
Enhanced CAR T cell
November 12th 2020

Radiation Does Not Disrupt CAR T-Cell Therapy in Patients With MM, Study Finds

Jared Kaltwasser
New research suggests it’s not disruptive to give radiation therapy to patients who are awaiting CAR T-cell therapy for relapsed or refractory multiple myeloma.
Multiple myeloma iPad display
November 10th 2020

Once-Weekly KRd Shows Promise in Newly Diagnosed MM

Jared Kaltwasser
Patients with newly diagnosed multiple myeloma often receive twice-weekly triplet regimens of carfilzomib, lenalidomide, and dexamethasone (KRd). New data suggest less frequent dosing can be equally successful.
Circulating Cell-Free DNA Could Be Marker of Progression in Multiple Myeloma
November 6th 2020

Circulating Cell-Free DNA Could Be Marker of Progression in Multiple Myeloma

Jared Kaltwasser
A new study suggests a potential new marker that could be used to track response to therapy and disease progression in patients with multiple myeloma.
Carfilzomib molecule
November 3rd 2020

New Analysis Aims to Characterize Patients With Best Carfilzomib Responses

Jared Kaltwasser
There did not appear to be any particular patient characteristics linked with best responses to carfilzomib in patients with multiple myeloma, with the exception of low serum lactate dehydrogenase.
Multiple myeloma
October 29th 2020

Use of Triplet Therapy Rose in R/R MM as Deaths Declined, Study Finds

Jared Kaltwasser
Newer therapies have led to a boost in the number of patients with relapsed or refractory multiple myeloma (R/R MM) who are prescribed triplet regimens. As that shift has occurred, death rates appear to have dropped.
Older Patient
October 22nd 2020

Patients With MM Living Longer, but Elderly Still Face Worse Survival

Jared Kaltwasser
New data show that despite major improvements in survival rates in patients with multiple myeloma (MM), older patients with the malignancy have benefited less than younger patients.
Drops in Circulating MicroRNA-451a Could Be Sign of MM Relapse
October 21st 2020

Drops in Circulating MicroRNA-451a Could Be Sign of MM Relapse

Jared Kaltwasser
Investigators may have found a minimally invasive way to predict which patients with multiple myeloma are about to experience a relapse.
Drug cost concept
October 13th 2020

CML Treatment Costs Continue to Rise Despite Availability of Generic Imatinib

Jared Kaltwasser
Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib.
Intestines
October 13th 2020

Colon Perforations in MM, While Rare, Linked With Corticosteroids

Jared Kaltwasser
A new report confirms earlier research that colon perforation in multiple myeloma is associated with corticosteroids, though the exact cause of the apparent link is not known.
Picture of bacteria
October 7th 2020

MM Staging, Severe Anemia Linked With High Infection and Mortality Risk

Jared Kaltwasser
Newly diagnosed patients with multiple myeloma (MM) face a high risk of infection. A new study helps elucidate key risk factors.
MRD Potential in MM Undeniable, Even if Not Ready for Use Yet, Review Says
September 30th 2020

MRD Potential in MM Undeniable, Even if Not Ready for Use Yet, Review Says

Jared Kaltwasser
A new review article said there are hurdles to bringing minimal residual disease (MRD) into the clinic as a decision-making tool, but the day is likely not far away.
Frailty Definitions Too Imprecise in Patients With MM, New Paper Suggests
September 27th 2020

Frailty Definitions Too Imprecise in Patients With MM, New Paper Suggests

Jared Kaltwasser
A subset of patients with multiple myeloma (MM) are not eligible for the most effective therapies, but a new study suggests clinicians may be inaccurately defining that subset.
Medical question image
September 23rd 2020

Review Updates Mechanisms Underlying Proteasome Inhibitor Resistance in MM

Jared Kaltwasser
Proteasome inhibitors have brought major advances in the treatment of multiple myeloma (MM), but eventual drug resistance remains a serious hurdle.
FDA Accepts Anti-BCMA Ide-cel for MM for Priority Review
September 22nd 2020

FDA Accepts Anti-BCMA Ide-cel for MM for Priority Review

Allison Inserro
FDA will review the first chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of multiple myeloma (MM) in adults who have not responded or have relapsed after at least 3 other therapies.
Treatment, Access to Caregivers Among Factors Affecting QOL in MM
September 18th 2020

Treatment, Access to Caregivers Among Factors Affecting QOL in MM

Jared Kaltwasser
A study of patients with multiple myeloma in China found many do not have access to a caregiver and most have to travel to another city to receive treatment.
Dollar sign
September 15th 2020

End-Organ Damage Leads to Spike in Economic Costs of Sickle Cell Disease

Jared Kaltwasser
Sickle cell disease is a costly disease for patients, but when those patients suffer from end-organ damage, the costs jump significantly.
Study Finds Limits to sCR Compared With MRD in Tracking MM Response
September 11th 2020

Study Finds Limits to sCR Compared With MRD in Tracking MM Response

Jared Kaltwasser
A new study suggests stringent complete response is less meaningful than minimal residual disease status when evaluating patients with multiple myeloma.
Education Level Linked to Outcomes in Patients With MM
September 9th 2020

Education Level Linked to Outcomes in Patients With MM

Jared Kaltwasser
New data suggests a patient’s education level can be an important factor in the disease outcomes of patients with multiple myeloma.
Red blood cells
September 3rd 2020

Combination Therapy Benefits High-Risk Patients With MM, Study Says

Jared Kaltwasser
A new analysis found patients with high-cytogenetic-risk multiple myeloma benefitted from adding daratumumab to their therapy.
plasma cells
August 31st 2020

Plasma Exchange Therapy MM Use, Cost Rose During Past 25 Years

Jared Kaltwasser
A new analysis finds therapeutic plasma exchange has become more costly, and more common among patients with multiple myeloma.
Picture of red blood cells
August 26th 2020

MRD an Exciting Advance, but Not Ready for MM Care Yet, Review Says

Jared Kaltwasser
A new opinion article suggests minimal residual disease (MRD) is not yet ready for “prime time” in the clinic, even though it’s already making a major impact on clinical trials.
MWN logo
August 17th 2020

FDA Actions Include Third CAR T-cell Therapy

AJMC Staff
Evidence-Based Oncology regulatory updates for August 2020 feature coverage of Kite Pharma's new CAR T-cell therapy and selinexor in DLBCL.
Review: MM Outcomes Greatly Improving, but New Agents Still Needed
August 16th 2020

Review: MM Outcomes Greatly Improving, but New Agents Still Needed

Jared Kaltwasser
Investigators have made tremendous strides improving patient care in multiple myeloma (MM), but the authors of a new review article say much more work is needed.
MRD, Biomarkers in Multiple Myeloma
August 15th 2020

MRD, Biomarkers in Multiple Myeloma

AJMC Staff
Clinical updates for August 2020 featured in Evidence-Based Oncology.
MRD? We’re Aware of It, Say Oncologists, But We Don’t Use It for Decisions
August 14th 2020

MRD? We’re Aware of It, Say Oncologists, But We Don’t Use It for Decisions

Jared Kaltwasser
Most oncologists in a recent survey said they lack the knowledge and data to use measurable, or minimal, residual disease (MRD) as a decision-making tool in the treatment of multiple myeloma.
<1
...
789101112131415
...
29>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo